Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cervical Cancer Test Market and Screening Population Analysis, by Screening Type (Pap Smear, HPV DNA, VIA) Global Forecast to 2022 New Report at ReportsnReports


News provided by

ReportsnReports

26 Jul, 2017, 10:00 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, July 26, 2017 /PRNewswire/ --

The "Cervical Cancer Test Market and Screening Population Analysis, By Screening Type (Pap Smear, HPV DNA, VIA) Global Forecast to 2022" is a 306 Page report with 238 Figures and 25 Tables. This report provides a comprehensive assessment of the Cervical Cancer Test (Pap Smear, HPV DNA Test and VIA) Screening Market in terms of Value and Volume terms.

Complete report available at http://www.reportsnreports.com/reports/1135515-cervical-cancer-test-market-screening-population-analysis-by-screening-type-pap-smear-hpv-dna-via-global-forecast-to-2022.html. (Single User License Price US $1890)

Cervical cancer is one of the most prevalent forms of cancer affecting women all over the world. In most cases, the disease is attributed to genital Human Papilloma Virus (HPV) infection. As cervical cancer is a disease with long latent period, early detection and treatment of precancerous lesions is known to be highly effective in women who regularly participate in screening programs. The death rate due to cervical cancer has dropped in many developed countries, thus indicating the growing adoption of screening procedures, such as Pap test and HPV testing.

The cervical cancer test market is driven by growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infections, rising incidences of teenage sexual cases, increasing number of awareness programs for cervical cancer screening, introduction of low cost VIA test and government initiatives and funding. However, lack of healthcare infrastructure and awareness regarding cervical cancer screening are the major restraints for cervical cancer testing market.

Place a Direct Purchase order of this report at http://www.reportsnreports.com/purchase.aspx?name=1135515. (Single User License Price US $1890)

Key Highlights of the Report  

Cervical cancer is amongst one of the most common causes of deaths in the U.S. women. United States alone captured over 40 percent share of the global cervical cancer test market. Pap test held a majority share of the cervical cancer screening market on account of the high efficiency of this test, however, HPV test is steadily gaining prominence. VIA is the best screening option where access to Pap smear tests and HPV test is not available.

In 2016, Global cervical cancer test population was estimated at XXX Million. Cervical cancer incidence rate in Europe is estimated at 10.6 per 100,000 women population.

Asia Pacific and North American region are competing closely with each other to grab maximum share of the cervical cancer test population. Indonesia, China, India and Japan captures highest share of the Asian cervical cancer test population. North America captures highest share of the global cervical cancer test market followed by the European region. Germany, United Kingdom and France are the other top three leaders in cervical cancer test market. China and India are the top contributor to the VIA test market. Australia's National Cervical Cancer Screening Program will change from December 2017.

The 20 Countries covered in the report have been analyzed from 4 View Points:  

Cervical Cancer Test Population (2007 - 2022), Pap Smear Test Population (2007 - 2022),HPV DNA Test population (2007 - 2022), VIA Test Population (2007 - 2022), Cervical Cancer Mortality, Cervical Cancer Test Market (2007 - 2022), Pap Smear Test Market (2007 - 2022), HPV DNA Test Market (2007 - 2022), VIA Test Market (2007 - 2022), Global Cervical Cancer Test Market - Driving Factors and Challenges

Cervical Cancer Test Market & Screening Population Analysis - 20 Countries Covered: United States, Canada, United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, Japan, South Korea, Singapore, Malaysia, Australia, India, China, Thailand, Indonesia

Research Methodologies  

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents:  

1. Executive Summary

2. Global Cervical Cancer Test (Screening) Population & Forecast (2007 - 2022)

3. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022)

4. Global Cervical Cancer Test (Screening) Market & Forecast (2007 - 2022) - By Segment

5. Cervical Cancer Test (Screening) Population Share & Forecast (2007 - 2022)

6. Global Cervical Cancer Test (Screening) Market Share & Forecast (2007 - 2022)

7. United States - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

8. Canada - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

9. United Kingdom - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

10. France - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

11. Germany - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

12. Italy - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

13. Spain - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

14. Sweden - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

15. Switzerland - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

16. Norway - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

17. Netherlands - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

18. Japan - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

19. South Korea - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

20. Singapore - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

21. Malaysia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

22. India - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

23. China - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

24. Thailand - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

25. Indonesia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2022)

26. Australia - Cervical Cancer Test (Screening) Population and Market Analysis (2007 - 2017)

27. Cervical Cancer Test (Screening) Market - Driving Factors

28. Cervical Cancer Test (Screening) Market - Challenges

Related research titled "Cervical Cancer - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Explore more reports on the Healthcare market at http://www.reportsnreports.com/market-research/healthcare/.

Contact:  
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

Connect With Us on:   

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/p-216-igate-research.xml

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.